(Q44006876)

English

Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention

scientific article published in June 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

myocardial infarction

1 reference

based on heuristic

inferred from title

unstable angina

1 reference

based on heuristic

inferred from title

author name string

Howard C Herrmann

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Tomasz A Swierkosz

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Shiv Kapoor

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Danielle C Tardiff

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Peter M DiBattiste

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

John W Hirshfeld

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Bruce D Klugherz

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Daniel M Kolansky

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kathleen Magness

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Nicholas Valettas

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Robert L Wilensky

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1293-1297

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Rapid platelet-function assay: an automated and quantitative cartridge-based method

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902329-9

7 January 2021

Identifiers

10.1016/S0002-9149(02)02329-9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44006876&oldid=2105585041"